Expand AIM Menu
AIM MENU

AIM Latest Press Releases

-- August 12, 2026 --

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published 'Breaking Defense' Article Globe Newswire 8:44 AM

-- August 10, 2026 --

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen Toward Planned Phase 3 Development in Pancreatic Cancer Globe Newswire 8:36 AM

-- August 3, 2026 --

AIM ImmunoTech Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point Globe Newswire 8:33 AM

-- July 7, 2026 --

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program Globe Newswire 9:03 AM

-- June 24, 2026 --

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones Globe Newswire 8:29 AM

-- June 22, 2026 --

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series Globe Newswire 8:45 AM

-- June 18, 2026 --

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer Globe Newswire 9:01 AM

-- June 15, 2026 --

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency Globe Newswire 8:01 AM

-- June 9, 2026 --

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules Globe Newswire 9:29 AM

-- June 8, 2026 --

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer Globe Newswire 8:33 AM

-- June 4, 2026 --

AIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness Globe Newswire 8:55 AM

-- June 1, 2026 --

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones Globe Newswire 8:58 AM

-- May 27, 2026 --

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration Globe Newswire 8:47 AM

-- May 20, 2026 --

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Globe Newswire 3:02 PM

-- May 19, 2026 --

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities Globe Newswire 8:02 AM

-- May 14, 2026 --

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer Globe Newswire 8:41 AM

-- May 8, 2026 --

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds Globe Newswire 8:40 AM

-- May 7, 2026 --

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential Globe Newswire 8:23 AM

-- April 16, 2026 --

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP Globe Newswire 9:00 AM

-- April 13, 2026 --

AIM ImmunoTech Provides Routine Update on Annual Filings Globe Newswire 6:00 PM

-- April 9, 2026 --

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes